FDA Finalizes Guidance on Human Factors Information for Medical Device Marketing Submissions
The U.S. Food and Drug Administration (FDA) today issued a final guidance document titled "Content of Human Factors Information in Medical Device Marketing Submissions". This guidance establishes a risk-based framework to help manufacturers determine the appropriate level of human factors (HF) information to include in premarket submissions, including 510(k) notifications, Premarket Approval (PMA) applications, De Novo classification requests, and Humanitarian Device Exemption (HDE) applications.
The critical impact of user interface design on the safe and effective use of medical devices is a priority for the FDA. The goal of this guidance is to ensure that device user interfaces are designed to eliminate or reduce use errors that could lead to patient harm or compromised medical care.
A Risk-Based Approach to Submissions The guidance introduces three HF Submission Categories based on the identification of critical tasks and the presence of use-related risks:
- Category 1: Applies to modifications of existing authorized devices where there are no changes to the user interface, intended users, uses, use environment, training, or labeling. Submissions in this category require a conclusion and a high-level summary justifying that human factors considerations are unaffected.
- Category 2: For new or modified devices where the Use-Related Risk Analysis (URRA) identifies no critical tasks (for new devices) or no new or impacted critical tasks (for modified devices). It also applies when validation testing is not warranted due to simple interfaces or established history of safe use. Manufacturers must provide a clear rationale for the absence of validation data.
- Category 3: For devices where new critical tasks are introduced or existing ones are impacted and require validation. These submissions must include a comprehensive HFE/UE report featuring results from human factors validation testing, risk management measures, and a discussion of residual risks.
Harmonizing Safety and Innovation This guidance complements the 2016 FDA guidance, "Applying Human Factors and Usability Engineering to Medical Devices," which focuses on the HFE/UE development process. By providing a standardized structure for human factors information—including user interface descriptions, known use problem summaries, and detailed validation testing protocols—the FDA aims to increase review efficiency and reduce the need for additional information requests during the premarket process.
Implementation The FDA anticipates that industry will need time to operationalize these policies. These recommendations will generally apply to marketing submissions received by the Center for Devices and Radiological Health (CDRH) on or after August 1, 2026.
For more information and to download the full guidance document, please visit the FDA’s official website.
About the FDA CDRH: The Center for Devices and Radiological Health (CDRH) is responsible for protecting and promoting the public health by ensuring the safety, effectiveness, and quality of medical devices and safe radiation-emitting products.